Vaccines by Oxford University-Serum Institute of India, Moderna, approved to advance to phase 2 trials, with more than 140 participants enrolled in broader trial
Vaccines by Oxford University-Serum Institute of India, Moderna, approved to advance to phase 2 trials, with more than 140 participants enrolled in broader trial
Declared in the Democratic Republic of the Congo in May this year, the 17th Ebola epidemic is already the deadliest in the country's history. Next week, two vaccine-candidates enter clinical trials, the World Health Organization announced this Tuesday.